Abstract
The challenges of transferring biomedical advances and non-biomedical technological innovations in HIV prevention and treatment to the field, are a theme of this year's XVII International AIDS Conference.
In the HIV field, innovations are often understood in exclusively biomedical or psychosocial terms. Related to these understandings are well-worn disciplinary distinctions. Thus vaccines and drug treatments are typically understood as biotechnological.